T
Talmadge E. King
Researcher at University of California, San Francisco
Publications - 215
Citations - 48569
Talmadge E. King is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Interstitial lung disease. The author has an hindex of 88, co-authored 214 publications receiving 43290 citations. Previous affiliations of Talmadge E. King include National Jewish Health & University of California.
Papers
More filters
Journal Article
Idiopathic Pulmonary Fibrosis
Leslie C. Watters,Marvin I. Schwarz,Reuben M. Cherniack,James A. Waldron,Thaddeus L. Dunn,Ray E. Stanford,Talmadge E. King +6 more
TL;DR: Recent data on the clinical course, therapeutic options, and underlying mechanisms thought to be involved in the pathogenesis of idiopathic pulmonary fibrosis are reviewed.
Journal ArticleDOI
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Brett Ley,Christopher J. Ryerson,Eric Vittinghoff,Jay H. Ryu,Sara Tomassetti,Joyce S. Lee,Venerino Poletti,Matteo Buccioli,Brett M. Elicker,Kirk D. Jones,Talmadge E. King,Harold R. Collard +11 more
TL;DR: The GAP models use commonly measured clinical and physiologic variables to predict mortality in patients with IPF and perform similarly in pooled follow-up visits.
Journal ArticleDOI
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Talmadge E. King,Jürgen Behr,Kevin K. Brown,Roland M. du Bois,Lisa Lancaster,Joao A. de Andrade,Gerd Stähler,Isabelle Leconte,Sébastien Roux,Ganesh Raghu +9 more
TL;DR: The primary objective in the Bosentan Use in Interstitial Lung Disease-3 trial was not met and bosentan was well tolerated.
Journal ArticleDOI
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.
Harold R. Collard,Talmadge E. King,Becki Bucher Bartelson,Jason S. Vourlekis,Marvin I. Schwarz,Kevin K. Brown +5 more
TL;DR: Evaluated changes in clinical and physiological variables over time for survival time in 81 patients with biopsy-proven idiopathic pulmonary fibrosis found that changes in dyspnea score, total lung capacity, FVC, partial pressure of arterial oxygen, oxygen saturation, and alveolar-arterial oxygen gradient were predictive of survival time after adjustment for baseline values.
Journal ArticleDOI
A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Ganesh Raghu,Kevin K. Brown,Williamson Z. Bradford,Karen M. Starko,Paul W. Noble,David A. Schwartz,Talmadge E. King +6 more
TL;DR: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life.